Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EPIX 
ESSA Pharma Inc (EPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EPIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.74
1 Year Target Price $1.74
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.3% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.79M USD | Price to earnings Ratio - | 1Y Target Price 1.74 |
Price to earnings Ratio - | 1Y Target Price 1.74 | ||
Volume (30-day avg) 2 | Beta 1.58 | 52 Weeks Range 1.40 - 7.88 | Updated Date 06/30/2025 |
52 Weeks Range 1.40 - 7.88 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.48% | Return on Equity (TTM) -23.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -37243905 | Price to Sales(TTM) - |
Enterprise Value -37243905 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.09 | Shares Outstanding 44388600 | Shares Floating 28160984 |
Shares Outstanding 44388600 | Shares Floating 28160984 | ||
Percent Insiders 6.02 | Percent Institutions 69.31 |
Analyst Ratings
Rating 2 | Target Price 1.74 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ESSA Pharma Inc
Company Overview
History and Background
ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer. Founded in 2009, it has focused on developing drugs targeting the N-terminal domain (NTD) of the androgen receptor (AR). The company has evolved from early research to clinical-stage development.
Core Business Areas
- Prostate Cancer Therapeutics: ESSA focuses on developing and commercializing therapies specifically for the treatment of prostate cancer, particularly castration-resistant prostate cancer (CRPC).
Leadership and Structure
David Parkinson serves as the President and CEO. The company has a board of directors overseeing its strategic direction and operations.
Top Products and Market Share
Key Offerings
- EPI-7386: EPI-7386 is ESSA's lead product candidate, an NTD inhibitor targeting the androgen receptor. It is currently in clinical trials for CRPC. There is no current market share data as it is still in development. Competitors include companies developing other AR inhibitors or treatments for CRPC such as Johnson & Johnson (ERLEADA), Pfizer (XTANDI), and AstraZeneca (LYNPARZA).
Market Dynamics
Industry Overview
The prostate cancer therapeutics market is a large and growing market driven by the aging population and increasing prevalence of prostate cancer. There is significant unmet need for new and effective therapies, particularly for CRPC.
Positioning
ESSA Pharma is positioned as an innovator in the prostate cancer therapeutics market, focusing on a novel mechanism of action (NTD inhibition). Its competitive advantage lies in its unique approach to targeting the androgen receptor.
Total Addressable Market (TAM)
The global prostate cancer therapeutics market is estimated to reach USD 12.9 billion by 2028. ESSA Pharma aims to capture a portion of this market with its novel therapies. Their position will be determined by the success of their clinical trials and commercialization strategies.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (NTD inhibition)
- Promising preclinical and early clinical data for EPI-7386
- Experienced management team focused on prostate cancer
- Strong intellectual property portfolio
Weaknesses
- Single product candidate (EPI-7386)
- High reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- No approved products generating revenue
Opportunities
- Potential for breakthrough therapy designation and accelerated approval
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of pipeline with additional NTD inhibitors or other prostate cancer therapies
- Favorable regulatory environment for cancer therapeutics
Threats
- Clinical trial failures or delays
- Competition from existing and emerging prostate cancer therapies
- Regulatory hurdles and changing approval requirements
- Patent challenges and loss of exclusivity
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- AZN
Competitive Landscape
ESSA Pharma faces competition from established pharmaceutical companies with approved prostate cancer therapies. ESSA's advantage lies in its novel mechanism of action, but it must demonstrate clinical efficacy and safety to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: ESSA's historical growth has been characterized by the advancement of its lead product candidate through preclinical and early clinical stages.
Future Projections: Future growth is dependent on the success of EPI-7386 in clinical trials and its potential commercialization. Analyst estimates will vary based on trial outcomes and market adoption potential. (No numerical data provided as exact financials change frequently and require live access.)
Recent Initiatives: Recent initiatives include ongoing clinical trials for EPI-7386, presentations at scientific conferences, and potential collaborations with other companies.
Summary
ESSA Pharma is a clinical-stage biopharmaceutical company focused on a novel approach to prostate cancer treatment. Success hinges on the clinical trial outcomes of EPI-7386. While the novel mechanism offers a potential advantage, the company faces significant financial and regulatory hurdles common to companies of its size. ESSA needs to manage its cash burn rate and successfully navigate the clinical trial process to achieve its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ESSA Pharma Inc. Investor Relations, SEC Filings, Market Research Reports, Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ESSA Pharma Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2015-07-09 | President, CEO & Director Dr. David Ross Parkinson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.essapharma.com |
Full time employees 35 | Website https://www.essapharma.com | ||
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.